Grifols reveals 2013 results

Grifols finished the last financial year with revenues of 2,741.7 million euros (2,292 million pounds).

This is an increase of 4.6 percent on 2012 figures and the company stressed its geographical diversification of sales went some way to mitigating the effect of volatility in exchange rates.

In 2013, Grifols consolidated its position as the third largest producer of plasma derivatives, finishing with a market share of approximately 20 percent.

Grifols also managed to build a competitive position in the three diagnostics specialities in which it operates.

The financial period included the acquisition of Novartis' transfusions and immunology diagnostics unit, which was completed in January 2014. The company explained this move will allow the group to expand further in the diagnostics segment in the coming 12 months.

Grifols' hospital division retained its position as Spain's leading provider of intravenous solutions.